EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Enhanced angiogenesis of human umbilical vein endothelial cells via THP‐1‐derived M2c‐like macrophages and treatment with proteasome inhibitors ‘bortezomib and ixazomib’

Selin Engür-Öztürk iD, Elif Kaya-Tİlkİ iD, Zerrin Cantürk iD, Miriş Dİkmen iD

APMIS · 2024

DOI: 10.1111/apm.13426 ↗

Kurz gefasst

Fachartikel in der Zeitschrift APMIS, 2024. Verfasst von Selin Engür-Öztürk und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Services, Tavas Vocational School of Health Services, Pamukkale University, Denizli, Turkey. Hauptthemen laut MEDLINE: Bortezomib, Glycine, Human Umbilical Vein Endothelial Cells, Proteasome Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Türkiye Bilimsel ve Teknolojik Araştırma Kurumu.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The leading cause of cancer‐related death is lung cancer, with metastasis being the most common cause of death. To elucidate the role of macrophages in lung cancer and angiogenesis processes, we established an in vitro co‐culture model of A549 or HUVEC with THP‐1 cells that polarized to M2c macrophages with hydrocortisone. The proteasome inhibitors bortezomib and ixazomib were investigated for their effects on proliferation, invasion, migration, metastasis, and angiogenesis pathways. The effects of bortezomib and ixazomib on gene expression in gene panels, including crucial genes related to angiogenesis and proteasomes, were investigated after the co‐culture model to determine these effects at the molecular level. In conclusion, bortezomib and ixazomib showed antiproliferative effects in both cells, as well as in M2c macrophage co‐culture. M2c macrophages also increased invasion in A549 cells and both invasion and migration in HUVEC. mRNA expression upregulation, specifically in the NFKB and VEGF genes, supported the metastatic and angiogenic effects found in A549 and HUVEC with M2c macrophage co‐culture. Additionally, bortezomib inhibited the VEGFB pathway in HUVEC and NFKB1 in A549 cells. The significant findings obtained as a result of this study will provide information regarding angiogenesis induced by M2 macrophages.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BortezomibGlycineHuman Umbilical Vein Endothelial CellsProteasome InhibitorsBoron CompoundsCoculture TechniquesMacrophagesCell MovementHumansCell ProliferationTHP-1 CellsNeovascularization, PathologicA549 CellsAngiogenesis

Stichwörter der Autor:innen

HUVECbortezomibhydrocortisoneixazomibmacrophage

Substanzen

BortezomibGlycineProteasome InhibitorsBoron Compoundsixazomib

Autor:innen und Institutionen

  • Department of Pharmacy Services, Tavas Vocational School of Health Services, Pamukkale University, Denizli, Turkey.
  • Department of Pharmacology, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey.
  • Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey.

ORCID-Profile: Selin Engür-Öztürk, Elif Kaya-Tİlkİ, Zerrin Cantürk, Miriş Dİkmen

Förderung

  • Türkiye Bilimsel ve Teknolojik Araştırma Kurumu

Zitieren

APA

Engür-Öztürk, S., Kaya-Tİlkİ, E., Cantürk, Z., & Dİkmen, M. (2024). Enhanced angiogenesis of human umbilical vein endothelial cells via THP‐1‐derived M2c‐like macrophages and treatment with proteasome inhibitors ‘bortezomib and ixazomib’. APMIS. https://doi.org/10.1111/apm.13426

Vancouver

Engür-Öztürk S, Kaya-Tİlkİ E, Cantürk Z, Dİkmen M. Enhanced angiogenesis of human umbilical vein endothelial cells via THP‐1‐derived M2c‐like macrophages and treatment with proteasome inhibitors ‘bortezomib and ixazomib’. APMIS. 2024. doi:10.1111/apm.13426

BibTeX
@article{Engrztrk2024,
  author = {Engür-Öztürk, Selin and Kaya-Tİlkİ, Elif and Cantürk, Zerrin and Dİkmen, Miriş},
  title = {Enhanced angiogenesis of human umbilical vein endothelial cells via THP‐1‐derived M2c‐like macrophages and treatment with proteasome inhibitors ‘bortezomib and ixazomib’},
  journal = {APMIS},
  year = {2024},
  doi = {10.1111/apm.13426}
}
Kostenlos starten →